Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOMIC-Meso: Pegargiminase in Nonepithelioid Mesothelioma
NCT02709512Phase 3Completed
- Sponsor
- Polaris Group
- Start
- Aug 2017
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 3 trial of Pegargiminase in malignant pleural mesothelioma (MPM), sponsored by Polaris Group. Started Aug 2017; status: completed.
02
Drugs
Pegargiminase
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02709512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02709512.